ArticleBMC microbiology2026
Novel antifungal metabolites from Bacillus velezensis XYDY-1 effectively control peanut Cylindrocladium black rot caused by Calonectria ilicicola.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundCylindrocladium black rot of peanut is caused by the fungus Calonectria ilicicola (anamorph: Cylindrocladium parasiticum). This quarantined plants pathogen, causes this diseasethat threatens the healthy production of peanuts. The objective of this study was to screen andexplore the extracts of biocontrol bacteria against C. ilicicola.
resultsA bacterial strain XYDY-1 was isolated from saline-alkali soil samples collected near peanut plants and identified as Bacillus velezensis based on morphological characteristics, 16S rDNA, and gyrB sequence analyses. The bacterial suspension of XYDY-1 exhibited significant inhibitory effects on the growth of eight pathogenic fungi, including C. ilicicola, Aspergillus niger, Fusarium pseudograminearum, F. oxysporum, F. neocosmosporiellum, Sclerotium rolfsii, Rhizoctonia solanikühn, and Sclerotinia sclerotiorum. Extracellular enzyme assays revealed that XYDY-1 possessed protease, cellulase, amylase, chitinase, and β-1,3-glucanase activities. Furthermore, genomic analysis confirmed the presence of genes srfAD, fenB, ituA, and bmyA, which encode surfactin, fengycin, iturin, and bacillomycin D, respectively, all of which contribute to the inhibition of hyphal growth. Ultra-high-performance liquid chromatography coupled with quadrupole-electrostatic field orbitrap high-resolution tandem mass spectrometry (UPLC-QE Orbitrap MS/MS) analysis detected antifungal compounds in B. velezensis metabolites, including 8-hydroxyquinoline, tunicamycin, Validamycin A, chloramphenicol palmitate, pyocyanin, and Surfactin C. 8-Hydroxyquinoline, tunicamycin, Surfactin C and Validamycin A exhibited significant antifungal activity in assays conducted with pure compounds. Of these, 8-hydroxyquinoline at a concentration of 10 mg/mL displayed the highest efficacy, yielding an inhibition rate of 98.31%. Additionally, greenhouse pot experiments demonstrated that the culture filtrate of XYDY-1 significantly promoted peanut plant growth, increasing fresh and dry biomass by 39.02% and 39.09%, respectively, compared to control treatments with culture medium alone. Moreover, the culture filtrate enhanced peanut resistance to C. ilicicola, achieving a biocontrol efficacy exceeding 56.41%.
conclusionB. velezensis XYDY-1, a plant-growth-promoting rhizobacterium, was able to protect peanuts from C. ilicicola infection and is a promising biocontrol agent.It can provide scientific basis for the development of new biological control pesticides, reduce the use of chemical pesticides, and promote the sustainable development of agriculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.